Phase I/II study of S-1 combined with biweekly irinotecan chemotherapy in previously treated advanced non-small cell lung cancer

被引：0
|
作者：
Hiroki Goya
Hiroshi Kuraishi
Shigeru Koyama
Takashi Ichiyama
Fumiaki Yoshiike
Kazuya Hirai
Toshihiko Agatsuma
Kazunari Tateishi
Shintaro Kanda
Hiroshi Yamamoto
Keishi Kubo
Tomonobu Koizumi
机构：
[1] Nagano Red Cross Hospital,Respiratory Division
[2] Nagano Municipal Hospital,Respiratory Division
[3] Shinshu University School of Medicine,First Department of Internal Medicine
[4] Shinshu University Hospital School of Medicine,Division of Clinical Oncology, Comprehensive Cancer Center
来源：
Cancer Chemotherapy and Pharmacology | 2012年 / 70卷
关键词：
Chemo-refractory; Salvage chemotherapy; Second line; CTP-11;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：691 / 697
页数：6
相关论文
共 50 条
  • [31] Phase II study of pemetrexed plus oxaliplatin for platinum-resistant advanced or metastatic non-small cell lung cancer patients
    Dae Ho Lee
    Chang-Min Choi
    Sang-We Kim
    Cheolwon Suh
    Jung-Shin Lee
    Medical Oncology, 2012, 29 : 640 - 643
  • [32] A phase II study of irinotecan plus cisplatin for patients with advanced stage IIIB or IVNSCLC previously treated with nonplatinum-based chemotherapy
    Kim, Heung T.
    Han, Ji-Youn
    Lee, Dae H.
    Chun, Jong H.
    Lee, Hong G.
    Lee, Jae J.
    Kim, Hyae Y.
    Lee, Sung Y.
    Lee, Jin S.
    CANCER, 2006, 107 (04) : 799 - 805
  • [33] Second-line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy - A phase II trial
    Tas, F
    Demir, C
    Camlica, H
    Ustuner, Z
    Topuz, E
    MEDICAL ONCOLOGY, 2004, 21 (03) : 233 - 240
  • [34] Weekly docetaxel as second-line therapy in non-small cell lung cancer: a phase II study
    Rossi, D
    Graziano, F
    Ugolini, M
    Dennetta, D
    Alessandroni, P
    Catalano, V
    Giordani, P
    Fedeli, SL
    Fedeli, A
    Catalano, G
    TUMORI JOURNAL, 2004, 90 (01): : 50 - 53
  • [35] An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with cisplatin-based chemotherapy. A phase II study of the Hellenic Co-Operative Oncology Group
    Pectasides, D
    Kalofonos, HP
    Samantas, E
    Nicolaides, C
    Papacostas, P
    Onyenadum, A
    Visvikis, A
    Skarlos, D
    Fountzilas, G
    ANTICANCER RESEARCH, 2001, 21 (4B) : 3005 - 3010
  • [36] Mitomycin plus vinorelbine salvage chemotherapy in non-small cell lung cancer: A prospective study
    Berghmans, Thierry
    Gourcerol, Delphine
    Lafitte, Jean-Jacques
    Kotsori, Katerina
    Paesmans, Marianne
    Scherpereel, Arnaud
    Leclercq, Nathalie
    Sculier, Jean-Paul
    LUNG CANCER, 2008, 61 (03) : 378 - 384
  • [37] Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy
    Chen, YM
    Perng, RP
    Lin, WC
    Wu, HW
    Tsai, CM
    Whang-Peng, J
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002, 25 (05): : 509 - 512
  • [38] Phase II study of gemcitabine and vinorelbine combination chemotherapy in patients with non-small-cell lung cancer not responding to previous chemotherapy
    Chen, YM
    Perng, RP
    Lee, CS
    Lin, WC
    Tsai, CM
    Whang-Peng, J
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2003, 26 (06): : 567 - 570
  • [39] Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC): A multicenter phase II study
    Kakolyris, Stylianos
    Ziras, Nikolaos
    Vamvakas, Lambros
    Varthalitis, John
    Papakotoulas, Pavlos
    Syrigos, Kostas
    Vardakis, Nikolaos
    Kalykaki, Antonia
    Amarantidis, Kiriakos
    Georgoulias, Vassilis
    LUNG CANCER, 2006, 54 (03) : 347 - 352
  • [40] Second-line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapyA phase II trial
    Faruk Tas
    Cumhur Demir
    Hakan Camlica
    Zeki Ustuner
    Erkan Topuz
    Medical Oncology, 2004, 21 : 233 - 240
12345